시장보고서
상품코드
1442280

세계의 마이크로바이옴 진단 시장 : 제품별, 기술별, 샘플별, 용도별 - 예측(-2028년)

Microbiome Diagnostics Market by Product (Kits & Reagents, Instruments), Technology (16s rRNA Sequencing, Shot Gun Metagenomics, Metatranscriptomics), Sample (Fecal, Saliva, Skin), Application (GI, Metabolic Disorders) - Global Forecast to 2028

발행일: | 리서치사: MarketsandMarkets | 페이지 정보: 영문 179 Pages | 배송안내 : 즉시배송

    
    
    


■ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계 마이크로바이옴 진단 시장 규모는 2023년 1억 4,600만 달러에서 예측 기간 동안 15.5%의 연평균 복합 성장률(CAGR)을 기록하며 2028년에는 3억 달러 규모로 성장할 것으로 예상됩니다.

마이크로바이옴 진단에 대한 인식 개선, 개인 맞춤형 의료에 대한 수요 증가, 질병 발생률 증가 등의 요인으로 인해 이 시장의 성장이 촉진되고 있습니다.

조사 범위
조사 대상년도 2022-2028년
기준년도 2023년
예측 기간 2023-2028년
검토 단위 금액(USD)
부문 제품, 기술, 샘플, 용도, 최종사용자, 지역
대상 지역 북미, 유럽, 아시아태평양 및 기타 지역

제품별로는 시약 및 키트가 가장 큰 점유율을 보이고 있습니다. 성장의 주요 원동력은 마이크로바이옴 기반 진단 절차에서 시약&키트의 반복적인 사용과 전 세계적으로 수행되는 마이크로바이옴 기반 검사 증가입니다. 또한, 효율적인 결과와 진단 정확도를 제공하는 우수한 시약&키트의 출시도 이 부문의 성장에 기여하고 있습니다.

기술별로는 16S rRNA 시퀀싱 부문이 예측 기간 동안 큰 성장률을 보일 것으로 예상됩니다. 모세관 시퀀싱이나 PCR 기반 접근법에 비해 16S rRNA 시퀀싱은 배양이 필요 없는 기술로, 연구자들은 샘플 내 전체 미생물 군집을 분석할 수 있으며, NGS 기반 16S rRNA 시퀀싱은 한 번의 시퀀싱 실행으로 많은 수의 샘플을 조합할 수 있기 때문에 샘플을 한 번의 시퀀싱 실행으로 결합할 수 있기 때문에 기존 방법으로는 찾을 수 없는 박테리아 균주를 식별할 수 있는 비용 효율적인 방법입니다.

지역별로는 아시아태평양이 가장 큰 성장세를 보이고 있습니다. 이 지역의 높은 성장의 배경에는 아시아 국가들의 질병 증가, 마이크로바이옴 연구 활동의 활성화가 있습니다.

세계 마이크로바이옴 진단(Microbiome Diagnostics) 시장을 조사했으며, 시장 개요, 시장 영향요인 및 시장 기회 분석, 기술 및 특허 동향, 규제 환경, 사례연구, 시장 규모 추이 및 예측, 각종 부문별/지역별 상세 분석, 경쟁 구도, 주요 기업 프로파일 등의 정보를 전해드립니다.

목차

제1장 서론

제2장 조사 방법

제3장 주요 요약

제4장 프리미엄 인사이트

제5장 시장 개요

  • 시장 역학
    • 성장 촉진요인
    • 성장 억제요인
    • 기회
    • 과제
  • 밸류체인 분석
  • 공급망 분석
  • Porter의 Five Forces 분석
  • 주요 이해관계자와 구입 기준
  • 규제 상황
  • 생태계 분석
  • 특허 분석
  • 주요 컨퍼런스 및 이벤트
  • 가격 분석
  • 고객의 비즈니스에 영향을 미치는 동향/파괴적 변화
  • 기술 분석
  • 무역 분석

제6장 마이크로바이옴 진단 시장 : 제품별

  • 키트 및 시약
  • 기기

제7장 마이크로바이옴 진단 시장 : 기술별

  • 16s rRNA 시퀀싱
  • 샷건 메타게노믹스
  • METATRANSCRIPTOMICS
  • 기타

제8장 마이크로바이옴 진단 시장 : 샘플별

  • 대변
  • 타액
  • 피부
  • 기타

제9장 마이크로바이옴 진단 시장 : 용도별

  • 잴병 진단 용도
    • 위장 장애
    • 대사장애증
    • 기타
  • 연구 용도

제10장 마이크로바이옴 진단 시장 : 최종사용자별

  • 병원
  • 연구기관
  • 제약 및 바이오테크놀러지 기업

제11장 마이크로바이옴 진단 시장 : 지역별

  • 북미
  • 유럽
  • 아시아태평양
  • 기타 지역

제12장 경쟁 구도

  • 개요
  • 주요 기업의 전략/유력 기업
  • 매출 분석
  • 시장 점유율 분석
  • 기업 평가 매트릭스
  • 신규 기업/중소기업 평가 매트릭스
  • 경쟁 시나리오·동향

제13장 기업 개요

  • 주요 기업
    • GENETIC ANALYSIS AS
    • DNA GENOTEK(ORASURE TECHNOLOGIES, INC.)
    • MICROBA LIFE SCIENCES
    • ILLUMINA INC.
    • OXFORD NANOPORE TECHNOLOGIES, PLC
    • BIOME OXFORD LTD.
    • VIENNALAB DIAGNOSTICS GMBH
    • METABIOMICS
    • VIOME LIFE SCIENCES
    • LUXIA SCIENTIFIC
    • SUN GENOMICS
    • ATLAS BIOMED
    • QUANTBIOME, INC.(DBA OMBRE)
    • BECTON, DICKINSON AND COMPANY
    • DAYTWO
  • 기타 기업
    • MICRONOMA
    • TERAOMICS S.L.
    • FLIGHTPATH BIOSCIENCES
    • MICROBIOME RESEARCH PVT. LTD.
    • ORIGIN SCIENCES
    • LEUCINE RICH BIO PRIVATE LIMITED
    • DECODE AGE
    • EVVY
    • ALPHABIOMICS, LTD.
    • GOODGUT

제14장 부록

LSH 24.03.13

The global microbiome diagnostics market is valued at an estimated USD 146 million in 2023 and is projected to reach USD 300 million by 2028, at a CAGR of 15.5% during the forecast period. Market growth is driven by factors such as increasing awareness of microbiome diagnostics, increasing demand of personalize medicine and increasing incidences of diseases.

Scope of the Report
Years Considered for the Study2022-2028
Base Year2023
Forecast Period2023-2028
Units ConsideredValue (USD) Million
SegmentsProduct, Technology, Sample, Application, End User, and Region
Regions coveredNorth America, Europe, Asia Pacific, Rest of the World

"The reagents & kits to register the largest share of the microbiome diagnostics market, by product."

The global microbiome diagnostics market is segmented into reagents & kits and instruments on product. Market growth is largely driven by the repetitive use of reagents & kits for microbiome-based diagnostic procedures coupled with the increase in the volume of microbiome-based tests conducted worldwide. Moreover, the availability of better reagents & kits that offer efficient results and precision in diagnosis attributes to their growing requirement resulting in growth of the segment.

"16s rRNA sequencing segment to grow at a considerable rate among technology during the forecast period."

The microbiome diagnostics market is segmented into 16s rRNA sequencing, shotgun metagenomics, metatranscriptomics and other technologies. As compared to capillary sequencing or PCR-based approaches, 16S rRNA sequencing is a culture-free technique that enables researchers to analyze the entire microbial community within a sample. Due to its ability to combine many samples in a sequencing run, NGS-based 16S rRNA sequencing is a cost-effective technique for identifying bacterial strains that may not be found using traditional methods.

"Research application segment accounted for the largest share in the microbiome diagnostics market, by application."

The global microbiome diagnostics market is segmented into research application, disease diagnostic application. The application segment of disease diagnostic application accounted for a considerable share in 2022, primarily due to rising prevalence of diseases.

"Asia Pacific: The fastest-growing region in the microbiome diagnostics market."

The global microbiome diagnostics market is segmented into five regions - North America, Europe, the Asia Pacific, Rest of the World. The Asia Pacific region is expected to grow at the highest rate during the forecast period in the microbiome-based diagnostics market. The high growth in the region is due to the increasing incidences of diseases, increasing microbiome research activities in Asian countries.

The break-up of the profile of primary participants in the microbiome diagnostics market:

  • By Company Type: Tier 1 - 55%, Tier 2 - 40%, and Tier 3 - 5%
  • By Designation: C-level - 37%, D-level - 48%, and Others - 15%
  • By Region: North America - 56%, Europe - 20%, Asia Pacific - 17%, Rest of the World- 7%,

The key players in this market are DNA Genotek (Canada), Invivo Healthcare (UK), Microba Life Sciences (US), Genetic Analysis AS (Norway), Metabiomics (US), Teraomics (US), Becton, Dickinson and Company (US), BioMe Oxford Ltd (UK), Viennalab Diagnostics (Austria), Viome Life Sciences, Inc. (US), Luxia Scientific (France), DayTwo (US), Sun Genomics (US), Atlas Biomed (UK), Quantbiome, Inc. (US), GoodGut (US), Micronoma (US), FlightPath Biosciences (US), and Microbiome Research Pvt. Ltd. (India)

Research Coverage:

This research report categorizes the microbiome diagnostics market by product (reagents & kits and instruments), sample (feces, saliva, skin and other sample), technology (16s rRNA sequencing, shotgun metagenomics, metatranscriptomics and other technology), application (research application, disease diagnosis and monitoring), end user (research institutes, pharmaceutical and biotechnology companies, hospitals and other end user), and region (North America, Europe, Asia Pacific, Rest of the World). The scope of the report covers detailed information regarding the major factors, such as drivers, opportunities, and challenges, influencing the growth of the microbiome diagnostics market. A detailed analysis of the key industry players has been done to provide insights into their business overview, products offered, key strategies, acquisitions, and partnerships. New product launches and approvals, and recent developments associated with the microbiome diagnostics market. This report covers the competitive analysis of upcoming startups in the microbiome-based diagnostics market ecosystem.

Reasons to buy this report:

The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall microbiome diagnostics market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, challenges, and opportunities.

The report provides insights on the following pointers:

  • Analysis of key drivers (The collaborative efforts between the microbiome industry and academia for microbiome research and the growing demand for personalized medicine, growing awareness about the importance of the human microbiome diagnostics, rising incidences of disease), opportunities (Increased collaboration of key players and small innovative companies to work on new microbiome technologies), and challenges (Adverse impact of complex regulatory policies on commercialization of microbiome ) influencing the growth of the microbiome-based market
  • Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product launches in the microbiome diagnostics market.
  • Market Development: Comprehensive information about lucrative markets - the report analyses the microbiome diagnostics market across varied regions.
  • Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the microbiome diagnostics market
  • Competitive Assessment: In-depth assessment of market shares, growth strategies and product offerings of leading players like DNA Genotek (Canada), Invivo Healthcare (UK), Microba Life Sciences (US), and Genetic Analysis AS (Norway)among others in the microbiome-based diagnostics market strategies.

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 STUDY OBJECTIVES
  • 1.2 MARKET DEFINITION
    • TABLE 1 INCLUSIONS & EXCLUSIONS
  • 1.3 STUDY SCOPE
    • FIGURE 1 MICROBIOME-BASED DIAGNOSTICS MARKET SCOPE
    • 1.3.1 YEARS CONSIDERED
  • 1.4 CURRENCY CONSIDERED
  • 1.5 STAKEHOLDERS

2 RESEARCH METHODOLOGY

  • 2.1 RESEARCH DATA
    • FIGURE 2 MICROBIOME-BASED DIAGNOSTICS MARKET: RESEARCH DESIGN METHODOLOGY
    • 2.1.1 SECONDARY DATA
      • 2.1.1.1 Key data from secondary sources
    • 2.1.2 PRIMARY DATA
    • FIGURE 3 PRIMARY SOURCES
      • 2.1.2.1 Key data from primary sources
      • 2.1.2.2 Key industry insights
    • FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY- AND DEMAND-SIDE PARTICIPANTS
      • 2.1.2.3 Breakdown of primary interviews
    • FIGURE 5 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
  • 2.2 MARKET SIZE ESTIMATION
    • 2.2.1 BOTTOM-UP APPROACH
      • 2.2.1.1 Approach 1: Company revenue estimation approach
    • FIGURE 6 BOTTOM-UP APPROACH: COMPANY REVENUE ESTIMATION APPROACH
      • 2.2.1.2 Approach 2: Presentations of companies and primary interviews
      • 2.2.1.3 Approach 3: Primary research
      • 2.2.1.4 Growth forecast
      • 2.2.1.5 CAGR projections
    • FIGURE 7 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
    • 2.2.2 TOP-DOWN APPROACH
    • FIGURE 8 MICROBIOME-BASED DIAGNOSTICS MARKET: TOP-DOWN APPROACH
  • 2.3 DATA TRIANGULATION
    • FIGURE 9 DATA TRIANGULATION METHODOLOGY
  • 2.4 STUDY ASSUMPTIONS
  • 2.5 RESEARCH LIMITATIONS AND RISK ASSESSMENT
    • TABLE 2 RISK ASSESSMENT: MICROBIOME-BASED DIAGNOSTICS MARKET
  • 2.6 IMPACT OF RECESSION ON MICROBIOME-BASED DIAGNOSTICS MARKET

3 EXECUTIVE SUMMARY

    • FIGURE 10 MICROBIOME-BASED DIAGNOSTICS MARKET, BY PRODUCT, 2023 VS. 2028 (USD MILLION)
    • FIGURE 11 MICROBIOME-BASED DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023 VS. 2028 (USD MILLION)
    • FIGURE 12 MICROBIOME-BASED DIAGNOSTICS MARKET, BY SAMPLE, 2023 VS. 2028 (USD MILLION)
    • FIGURE 13 MICROBIOME-BASED DIAGNOSTICS MARKET, BY APPLICATION, 2023 VS. 2028 (USD MILLION)
    • FIGURE 14 MICROBIOME-BASED DIAGNOSTICS MARKET, BY END USER, 2023 VS. 2028 (USD MILLION)
    • FIGURE 15 GEOGRAPHICAL SNAPSHOT OF MICROBIOME-BASED DIAGNOSTICS MARKET

4 PREMIUM INSIGHTS

  • 4.1 MICROBIOME-BASED DIAGNOSTICS MARKET OVERVIEW
    • FIGURE 16 RISING DISEASE INCIDENCE AND TECHNOLOGICAL ADVANCEMENTS TO DRIVE MARKET GROWTH
  • 4.2 NORTH AMERICA: MICROBIOME-BASED DIAGNOSTICS MARKET, BY PRODUCT & COUNTRY (2022)
    • FIGURE 17 KITS & REAGENTS ACCOUNTED FOR LARGEST SHARE OF NORTH AMERICAN MARKET IN 2022
  • 4.3 MICROBIOME-BASED DIAGNOSTICS MARKET: GEOGRAPHICAL SNAPSHOT
    • FIGURE 18 CHINA AND INDIA TO WITNESS HIGHEST GROWTH RATES DURING FORECAST PERIOD
  • 4.4 MICROBIOME-BASED DIAGNOSTICS MARKET: GEOGRAPHIC MIX
    • FIGURE 19 APAC TO WITNESS HIGHEST GROWTH DURING FORECAST PERIOD
  • 4.5 MICROBIOME-BASED DIAGNOSTICS MARKET: DEVELOPED VS. EMERGING ECONOMIES
    • FIGURE 20 EMERGING ECONOMIES TO REGISTER HIGHER GROWTH DURING FORECAST PERIOD

5 MARKET OVERVIEW

  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    • FIGURE 21 MICROBIOME-BASED DIAGNOSTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
    • 5.2.1 DRIVERS
      • 5.2.1.1 Growing prevalence of chronic diseases
    • FIGURE 22 GLOBAL INCIDENCE OF DIABETES, 2021 VS. 2045
      • 5.2.1.2 Collaborative efforts between microbiome industry and academia for microbiome research
      • 5.2.1.3 Growing demand for personalized medicine
      • 5.2.1.4 Rising awareness about importance of human microbiomes
      • 5.2.1.5 Rising funding and investments in microbiome research
    • 5.2.2 RESTRAINTS
      • 5.2.2.1 End-user budget constraints in developing countries
    • 5.2.3 OPPORTUNITIES
      • 5.2.3.1 Increased collaboration between key players and small innovative companies to work on new microbiome technologies
    • TABLE 3 COLLABORATIONS IN MICROBIOME-BASED DIAGNOSTICS MARKET
    • 5.2.4 CHALLENGES
      • 5.2.4.1 Adverse impact of complex regulatory policies on commercialization of microbiome
  • 5.3 VALUE CHAIN ANALYSIS
    • FIGURE 23 VALUE CHAIN ANALYSIS: MAJOR VALUE ADDED DURING MANUFACTURING AND ASSEMBLY PHASES
  • 5.4 SUPPLY CHAIN ANALYSIS
    • FIGURE 24 DIRECT DISTRIBUTION-PREFERRED STRATEGY FOR PROMINENT COMPANIES
  • 5.5 PORTER'S FIVE FORCES ANALYSIS
    • 5.5.1 THREAT OF NEW ENTRANTS
    • 5.5.2 INTENSITY OF COMPETITIVE RIVALRY
    • 5.5.3 BARGAINING POWER OF BUYERS
    • 5.5.4 BARGAINING POWER OF SUPPLIERS
    • 5.5.5 THREAT OF SUBSTITUTES
  • 5.6 KEY STAKEHOLDERS & BUYING CRITERIA
    • 5.6.1 KEY STAKEHOLDERS IN BUYING PROCESS
    • FIGURE 25 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR TOP 2 END USERS
    • 5.6.2 BUYING CRITERIA
    • FIGURE 26 KEY BUYING CRITERIA FOR TOP 2 END USERS
  • 5.7 REGULATORY LANDSCAPE
    • 5.7.1 NORTH AMERICA
    • TABLE 4 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • 5.7.2 EUROPE
    • TABLE 5 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • 5.7.3 ASIA PACIFIC
    • TABLE 6 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • 5.7.4 REST OF THE WORLD
    • TABLE 7 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • 5.8 ECOSYSTEM ANALYSIS
    • TABLE 8 ROLE IN ECOSYSTEM
    • FIGURE 27 KEY PLAYERS OPERATING IN MICROBIOME-BASED DIAGNOSTICS MARKET
  • 5.9 PATENT ANALYSIS
  • 5.10 KEY CONFERENCES & EVENTS
    • TABLE 9 LIST OF CONFERENCES & EVENTS IN 2023-2024
  • 5.11 PRICING ANALYSIS
    • 5.11.1 AVERAGE SELLING PRICE TREND OF KEY PLAYERS, BY APPLICATION
    • TABLE 10 PRICE RANGE OF PRODUCTS OFFERED BY KEY PLAYERS FOR APPLICATIONS (USD)
  • 5.12 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
  • 5.13 TECHNOLOGY ANALYSIS
    • 5.13.1 DEVELOPMENT OF NOVEL MICROBIOME SAMPLING DEVICES
  • 5.14 TRADE ANALYSIS
    • TABLE 11 IMPORT DATA FOR HS CODE 902780, BY COUNTRY, 2018-2021 (USD MILLION)
    • TABLE 12 EXPORT DATA FOR HS CODE 902780, BY COUNTRY, 2018-2021 (USD MILLION)

6 MICROBIOME-BASED DIAGNOSTICS MARKET, BY PRODUCT

  • 6.1 INTRODUCTION
    • TABLE 13 MICROBIOME-BASED DIAGNOSTICS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
  • 6.2 KITS & REAGENTS
    • 6.2.1 KITS & REAGENTS TO DOMINATE MICROBIOME-BASED DIAGNOSTICS MARKET DURING FORECAST PERIOD
    • TABLE 14 MICROBIOME-BASED DIAGNOSTIC KITS & REAGENTS MARKET, BY REGION, 2021-2028 (USD MILLION)
  • 6.3 INSTRUMENTS
    • 6.3.1 INCREASING VOLUME OF BLOOD COLLECTION PROCEDURES TO DRIVE MARKET GROWTH
    • TABLE 15 MICROBIOME-BASED DIAGNOSTIC INSTRUMENTS MARKET, BY REGION, 2021-2028 (USD MILLION)

7 MICROBIOME-BASED DIAGNOSTICS MARKET, BY TECHNOLOGY

  • 7.1 INTRODUCTION
    • TABLE 16 MICROBIOME-BASED DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
  • 7.2 16S RRNA SEQUENCING
    • 7.2.1 ABILITY TO COMBINE MANY SAMPLES IN SEQUENCING RUN TO DRIVE DEMAND FOR NGS-BASED 16S RRNA SEQUENCING
    • TABLE 17 MICROBIOME-BASED DIAGNOSTICS MARKET FOR 16S RRNA SEQUENCING, BY REGION, 2021-2028 (USD MILLION)
  • 7.3 SHOTGUN METAGENOMICS
    • 7.3.1 ABILITY OF SHOTGUN METAGENOMICS TO PROVIDE DETAILED GENETIC INFORMATION TO BOOST DEMAND
    • TABLE 18 COMPARISON BETWEEN SHOTGUN METAGENOMICS AND 16S RRNA SEQUENCING
    • TABLE 19 MICROBIOME-BASED DIAGNOSTICS MARKET FOR SHOTGUN METAGENOMICS, BY REGION, 2021-2028 (USD MILLION)
  • 7.4 METATRANSCRIPTOMICS
    • 7.4.1 ONGOING TECHNOLOGICAL ADVANCEMENTS IN SEQUENCING INSTRUMENTS TO DRIVE GROWTH
    • TABLE 20 MICROBIOME-BASED DIAGNOSTICS MARKET FOR METATRANSCRIPTOMICS, BY REGION, 2021-2028 (USD MILLION)
  • 7.5 OTHER TECHNOLOGIES
    • TABLE 21 MICROBIOME-BASED DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2021-2028 (USD MILLION)

8 MICROBIOME-BASED DIAGNOSTICS MARKET, BY SAMPLE

  • 8.1 INTRODUCTION
    • TABLE 22 MICROBIOME-BASED DIAGNOSTICS MARKET, BY SAMPLE, 2021-2028 (USD MILLION)
  • 8.2 FECAL SAMPLES
    • 8.2.1 FECAL SAMPLES TO DOMINATE MICROBIOME-BASED DIAGNOSTICS MARKET DURING FORECAST PERIOD
    • TABLE 23 LIST OF MICROBIOME-BASED DIAGNOSTIC KITS FOR FECAL SAMPLES
    • TABLE 24 MICROBIOME-BASED DIAGNOSTICS MARKET FOR FECAL SAMPLES, BY REGION, 2021-2028 (USD MILLION)
  • 8.3 SALIVA SAMPLES
    • 8.3.1 ADVANCEMENTS IN ORAL DIAGNOSTICS TO DRIVE MARKET GROWTH
    • TABLE 25 LIST OF MICROBIOME-BASED DIAGNOSTIC KITS FOR SALIVA SAMPLES
    • TABLE 26 MICROBIOME-BASED DIAGNOSTICS MARKET FOR SALIVA SAMPLES, BY REGION, 2021-2028 (USD MILLION)
  • 8.4 SKIN SAMPLES
    • 8.4.1 GROWING FOCUS ON MICROBIOME RESEARCH ACTIVITIES TO BOOST MARKET
    • TABLE 27 LIST OF MICROBIOME-BASED DIAGNOSTIC KITS FOR SKIN SAMPLES
    • TABLE 28 MICROBIOME-BASED DIAGNOSTICS MARKET FOR SKIN SAMPLES, BY REGION, 2021-2028 (USD MILLION)
  • 8.5 OTHER SAMPLES
    • TABLE 29 LIST OF MICROBIOME-BASED DIAGNOSTIC KITS FOR OTHER SAMPLES
    • TABLE 30 MICROBIOME-BASED DIAGNOSTICS MARKET FOR OTHER SAMPLES, BY REGION, 2021-2028 (USD MILLION)

9 MICROBIOME-BASED DIAGNOSTICS MARKET, BY APPLICATION

  • 9.1 INTRODUCTION
    • TABLE 31 MICROBIOME-BASED DIAGNOSTICS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
  • 9.2 DISEASE DIAGNOSTIC APPLICATIONS
    • TABLE 32 MICROBIOME-BASED DIAGNOSTICS MARKET FOR DISEASE DIAGNOSTIC APPLICATIONS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 33 MICROBIOME-BASED DIAGNOSTICS MARKET FOR DISEASE DIAGNOSTIC APPLICATIONS, BY REGION, 2021-2028 (USD MILLION)
    • 9.2.1 GASTROINTESTINAL DISORDERS
      • 9.2.1.1 Growing incidence of gastrointestinal disorders to drive market growth
    • TABLE 34 MICROBIOME-BASED DIAGNOSTICS MARKET FOR GASTROINTESTINAL DISORDERS, BY REGION, 2021-2028 (USD MILLION)
    • 9.2.2 METABOLIC DISORDERS
      • 9.2.2.1 High prevalence of metabolic disorders to drive demand for microbiome-based diagnostic products
    • TABLE 35 MICROBIOME-BASED DIAGNOSTICS MARKET FOR METABOLIC DISORDERS, BY REGION, 2021-2028 (USD MILLION)
    • 9.2.3 OTHER DISEASE DIAGNOSTIC APPLICATIONS
    • TABLE 36 MICROBIOME-BASED DIAGNOSTICS MARKET FOR OTHER DISEASE DIAGNOSTIC APPLICATIONS, BY REGION, 2021-2028 (USD MILLION)
  • 9.3 RESEARCH APPLICATIONS
    • 9.3.1 GROWING RESEARCH ACTIVITIES TO BOOST MARKET
    • TABLE 37 MICROBIOME-BASED DIAGNOSTICS MARKET FOR RESEARCH APPLICATIONS, BY REGION, 2021-2028 (USD MILLION)

10 MICROBIOME-BASED DIAGNOSTICS MARKET, BY END USER

  • 10.1 INTRODUCTION
    • TABLE 38 MICROBIOME-BASED DIAGNOSTICS MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 10.2 HOSPITALS
    • 10.2.1 HOSPITALS ACCOUNTED FOR LARGEST SHARE OF MICROBIOME-BASED DIAGNOSTICS MARKET IN 2022
    • TABLE 39 MICROBIOME-BASED DIAGNOSTICS MARKET FOR HOSPITALS, BY REGION, 2021-2028 (USD MILLION)
  • 10.3 RESEARCH INSTITUTES
    • 10.3.1 GROWING FUNDING FOR MICROBIOME RESEARCH TO SUPPORT MARKET GROWTH
    • TABLE 40 MICROBIOME-BASED DIAGNOSTICS MARKET FOR RESEARCH INSTITUTES, BY REGION, 2021-2028 (USD MILLION)
  • 10.4 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
    • 10.4.1 GROWING FOCUS ON PERSONALIZED MEDICINE TO DRIVE DEMAND FOR MICROBIOME-BASED PRODUCTS
    • TABLE 41 MICROBIOME-BASED DIAGNOSTICS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2021-2028 (USD MILLION)

11 MICROBIOME-BASED DIAGNOSTICS MARKET, BY REGION

  • 11.1 INTRODUCTION
    • TABLE 42 NORTH AMERICA: MICROBIOME-BASED DIAGNOSTICS MARKET, BY REGION, 2021-2028 (USD MILLION)
  • 11.2 NORTH AMERICA
    • FIGURE 28 NORTH AMERICA: MICROBIOME-BASED DIAGNOSTICS MARKET SNAPSHOT
    • TABLE 43 NORTH AMERICA: MICROBIOME-BASED DIAGNOSTICS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 44 NORTH AMERICA: MICROBIOME-BASED DIAGNOSTICS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 45 NORTH AMERICA: MICROBIOME-BASED DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 46 NORTH AMERICA: MICROBIOME-BASED DIAGNOSTICS MARKET, BY SAMPLE, 2021-2028 (USD MILLION)
    • TABLE 47 NORTH AMERICA: MICROBIOME-BASED DIAGNOSTICS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 48 NORTH AMERICA: MICROBIOME-BASED DIAGNOSTICS MARKET FOR DISEASE DIAGNOSTIC APPLICATIONS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 49 NORTH AMERICA: MICROBIOME-BASED DIAGNOSTICS MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 11.2.1 US
      • 11.2.1.1 US to account for largest share of during forecast period
    • TABLE 50 US: MICROBIOME-BASED DIAGNOSTICS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 51 US: MICROBIOME-BASED DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 52 US: MICROBIOME-BASED DIAGNOSTICS MARKET, BY SAMPLE, 2021-2028 (USD MILLION)
    • TABLE 53 US: MICROBIOME-BASED DIAGNOSTICS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 54 US: MICROBIOME-BASED DIAGNOSTICS MARKET FOR DISEASE DIAGNOSTIC APPLICATIONS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 55 US: MICROBIOME-BASED DIAGNOSTICS MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 11.2.2 CANADA
      • 11.2.2.1 High prevalence of diseases in Canada to support market growth
    • TABLE 56 CANADA: MICROBIOME-BASED DIAGNOSTICS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 57 CANADA: MICROBIOME-BASED DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 58 CANADA: MICROBIOME-BASED DIAGNOSTICS MARKET, BY SAMPLE, 2021-2028 (USD MILLION)
    • TABLE 59 CANADA: MICROBIOME-BASED DIAGNOSTICS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 60 CANADA: MICROBIOME-BASED DIAGNOSTICS MARKET FOR DISEASE DIAGNOSTIC APPLICATIONS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 61 CANADA: MICROBIOME-BASED DIAGNOSTICS MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 11.2.3 NORTH AMERICA: RECESSION IMPACT
  • 11.3 EUROPE
    • TABLE 62 EUROPE: MICROBIOME-BASED DIAGNOSTICS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 63 EUROPE: MICROBIOME-BASED DIAGNOSTICS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 64 EUROPE: MICROBIOME-BASED DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 65 EUROPE: MICROBIOME-BASED DIAGNOSTICS MARKET, BY SAMPLE, 2021-2028 (USD MILLION)
    • TABLE 66 EUROPE: MICROBIOME-BASED DIAGNOSTICS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 67 EUROPE: MICROBIOME-BASED DIAGNOSTICS MARKET FOR DISEASE DIAGNOSTIC APPLICATIONS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 68 EUROPE: MICROBIOME-BASED DIAGNOSTICS MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 11.3.1 GERMANY
      • 11.3.1.1 Germany to dominate European microbiome-based diagnostics market during forecast period
    • TABLE 69 GERMANY: MICROBIOME-BASED DIAGNOSTICS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 70 GERMANY: MICROBIOME-BASED DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 71 GERMANY: MICROBIOME-BASED DIAGNOSTICS MARKET, BY SAMPLE, 2021-2028 (USD MILLION)
    • TABLE 72 GERMANY: MICROBIOME-BASED DIAGNOSTICS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 73 GERMANY: MICROBIOME-BASED DIAGNOSTICS MARKET FOR DISEASE DIAGNOSTIC APPLICATIONS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 74 GERMANY: MICROBIOME-BASED DIAGNOSTICS MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 11.3.2 FRANCE
      • 11.3.2.1 Growing number of microbiome sequencing start-ups to boost market growth
    • TABLE 75 FRANCE: MICROBIOME-BASED DIAGNOSTICS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 76 FRANCE: MICROBIOME-BASED DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 77 FRANCE: MICROBIOME-BASED DIAGNOSTICS MARKET, BY SAMPLE, 2021-2028 (USD MILLION)
    • TABLE 78 FRANCE: MICROBIOME-BASED DIAGNOSTICS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 79 FRANCE: MICROBIOME-BASED DIAGNOSTICS MARKET FOR DISEASE DIAGNOSTIC APPLICATIONS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 80 FRANCE: MICROBIOME-BASED DIAGNOSTICS MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 11.3.3 UK
      • 11.3.3.1 Supportive environment for microbiome sequencing R&D to support growth
    • TABLE 81 UK: MICROBIOME-BASED DIAGNOSTICS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 82 UK: MICROBIOME-BASED DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 83 UK: MICROBIOME-BASED DIAGNOSTICS MARKET, BY SAMPLE, 2021-2028 (USD MILLION)
    • TABLE 84 UK: MICROBIOME-BASED DIAGNOSTICS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 85 UK: MICROBIOME-BASED DIAGNOSTICS MARKET FOR DISEASE DIAGNOSTIC APPLICATIONS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 86 UK: MICROBIOME-BASED DIAGNOSTICS MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 11.3.4 REST OF EUROPE
    • TABLE 87 REST OF EUROPE: MICROBIOME-BASED DIAGNOSTICS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 88 REST OF EUROPE: MICROBIOME-BASED DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 89 REST OF EUROPE: MICROBIOME-BASED DIAGNOSTICS MARKET, BY SAMPLE, 2021-2028 (USD MILLION)
    • TABLE 90 REST OF EUROPE: MICROBIOME-BASED DIAGNOSTICS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 91 REST OF EUROPE: MICROBIOME-BASED DIAGNOSTICS MARKET FOR DISEASE DIAGNOSTIC APPLICATIONS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 92 REST OF EUROPE: MICROBIOME-BASED DIAGNOSTICS MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 11.3.5 EUROPE: RECESSION IMPACT
  • 11.4 ASIA PACIFIC
    • FIGURE 29 ASIA PACIFIC: MICROBIOME-BASED DIAGNOSTICS MARKET SNAPSHOT
    • TABLE 93 ASIA PACIFIC: MICROBIOME-BASED DIAGNOSTICS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 94 ASIA PACIFIC: MICROBIOME-BASED DIAGNOSTICS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 95 ASIA PACIFIC: MICROBIOME-BASED DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 96 ASIA PACIFIC: MICROBIOME-BASED DIAGNOSTICS MARKET, BY SAMPLE, 2021-2028 (USD MILLION)
    • TABLE 97 ASIA PACIFIC: MICROBIOME-BASED DIAGNOSTICS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 98 ASIA PACIFIC: MICROBIOME-BASED DIAGNOSTICS MARKET FOR DISEASE DIAGNOSTIC APPLICATIONS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 99 ASIA PACIFIC: MICROBIOME-BASED DIAGNOSTICS MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 11.4.1 CHINA
      • 11.4.1.1 Collaborations between academic institutes and private companies to drive growth
    • TABLE 100 CHINA: MICROBIOME-BASED DIAGNOSTICS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 101 CHINA: MICROBIOME-BASED DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 102 CHINA: MICROBIOME-BASED DIAGNOSTICS MARKET, BY SAMPLE, 2021-2028 (USD MILLION)
    • TABLE 103 CHINA: MICROBIOME-BASED DIAGNOSTICS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 104 CHINA: MICROBIOME-BASED DIAGNOSTICS MARKET FOR DISEASE DIAGNOSTIC APPLICATIONS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 105 CHINA: MICROBIOME-BASED DIAGNOSTICS MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 11.4.2 JAPAN
      • 11.4.2.1 Rising aging population to drive market growth
    • TABLE 106 JAPAN: MICROBIOME-BASED DIAGNOSTICS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 107 JAPAN: MICROBIOME-BASED DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 108 JAPAN: MICROBIOME-BASED DIAGNOSTICS MARKET, BY SAMPLE, 2021-2028 (USD MILLION)
    • TABLE 109 JAPAN: MICROBIOME-BASED DIAGNOSTICS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 110 JAPAN: MICROBIOME-BASED DIAGNOSTICS MARKET FOR DISEASE DIAGNOSTIC APPLICATIONS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 111 JAPAN: MICROBIOME-BASED DIAGNOSTICS MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 11.4.3 INDIA
      • 11.4.3.1 Increasing prevalence of diseases to drive market growth
    • TABLE 112 INDIA: MICROBIOME-BASED DIAGNOSTICS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 113 INDIA: MICROBIOME-BASED DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 114 INDIA: MICROBIOME-BASED DIAGNOSTICS MARKET, BY SAMPLE, 2021-2028 (USD MILLION)
    • TABLE 115 INDIA: MICROBIOME-BASED DIAGNOSTICS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 116 INDIA: MICROBIOME-BASED DIAGNOSTICS MARKET FOR DISEASE DIAGNOSTIC APPLICATIONS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 117 INDIA: MICROBIOME-BASED DIAGNOSTICS MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 11.4.4 REST OF ASIA PACIFIC
    • TABLE 118 REST OF ASIA PACIFIC: MICROBIOME-BASED DIAGNOSTICS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 119 REST OF ASIA PACIFIC: MICROBIOME-BASED DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 120 REST OF ASIA PACIFIC: MICROBIOME-BASED DIAGNOSTICS MARKET, BY SAMPLE, 2021-2028 (USD MILLION)
    • TABLE 121 REST OF ASIA PACIFIC: MICROBIOME-BASED DIAGNOSTICS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 122 REST OF ASIA PACIFIC: MICROBIOME-BASED DIAGNOSTICS MARKET FOR DISEASE DIAGNOSTIC APPLICATIONS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 123 REST OF ASIA PACIFIC: MICROBIOME-BASED DIAGNOSTICS MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 11.4.5 ASIA PACIFIC: RECESSION IMPACT
  • 11.5 REST OF THE WORLD
    • TABLE 124 REST OF THE WORLD: MICROBIOME-BASED DIAGNOSTICS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 125 REST OF THE WORLD: MICROBIOME-BASED DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 126 REST OF THE WORLD: MICROBIOME-BASED DIAGNOSTICS MARKET, BY SAMPLE, 2021-2028 (USD MILLION)
    • TABLE 127 REST OF THE WORLD: MICROBIOME-BASED DIAGNOSTICS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 128 REST OF THE WORLD: MICROBIOME-BASED DIAGNOSTICS MARKET FOR DISEASE DIAGNOSTIC APPLICATIONS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 129 REST OF THE WORLD: MICROBIOME-BASED DIAGNOSTICS MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 11.5.1 REST OF THE WORLD: RECESSION IMPACT

12 COMPETITIVE LANDSCAPE

  • 12.1 OVERVIEW
  • 12.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
    • TABLE 130 OVERVIEW OF STRATEGIES ADOPTED BY KEY MICROBIOME-BASED DIAGNOSTIC MANUFACTURERS
  • 12.3 REVENUE ANALYSIS
    • FIGURE 30 REVENUE ANALYSIS OF KEY PLAYERS
  • 12.4 MARKET SHARE ANALYSIS
    • TABLE 131 MICROBIOME-BASED DIAGNOSTICS MARKET: DEGREE OF COMPETITION
  • 12.5 COMPANY EVALUATION MATRIX
    • 12.5.1 STARS
    • 12.5.2 EMERGING LEADERS
    • 12.5.3 PERVASIVE PLAYERS
    • 12.5.4 PARTICIPANTS
    • FIGURE 31 MICROBIOME-BASED DIAGNOSTICS MARKET: COMPANY EVALUATION MATRIX
    • 12.5.5 COMPANY FOOTPRINT ANALYSIS
    • TABLE 132 COMPANY FOOTPRINT
    • TABLE 133 COMPANY PRODUCT FOOTPRINT
    • TABLE 134 COMPANY REGIONAL FOOTPRINT
  • 12.6 START-UP/SME EVALUATION MATRIX
    • 12.6.1 PROGRESSIVE COMPANIES
    • 12.6.2 RESPONSIVE COMPANIES
    • 12.6.3 DYNAMIC COMPANIES
    • 12.6.4 STARTING BLOCKS
    • FIGURE 32 MICROBIOME-BASED DIAGNOSTICS MARKET: START-UP/SME EVALUATION MATRIX, 2022
    • 12.6.5 COMPETITIVE BENCHMARKING
    • TABLE 135 MICROBIOME-BASED DIAGNOSTICS MARKET: DETAILED LIST OF KEY START-UPS/SMES
  • 12.7 COMPETITIVE SCENARIO & TRENDS
    • 12.7.1 PRODUCT LAUNCHES & APPROVALS
    • TABLE 136 MICROBIOME-BASED DIAGNOSTICS MARKET: PRODUCT LAUNCHES & APPROVALS, 2020-2023
    • 12.7.2 DEALS
    • TABLE 137 MICROBIOME-BASED DIAGNOSTICS MARKET: DEALS, 2020-2023

13 COMPANY PROFILES

  • 13.1 KEY PLAYERS
  • (Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments)**
    • 13.1.1 GENETIC ANALYSIS AS
    • TABLE 138 GENETIC ANALYSIS AS: COMPANY OVERVIEW
    • FIGURE 33 GENETIC ANALYSIS AS: COMPANY SNAPSHOT (2022)
    • 13.1.2 DNA GENOTEK (ORASURE TECHNOLOGIES, INC.)
    • TABLE 139 DNA GENOTEK: COMPANY OVERVIEW
    • FIGURE 34 ORASURE TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2022)
    • 13.1.3 MICROBA LIFE SCIENCES
    • TABLE 140 MICROBA LIFE SCIENCES: COMPANY OVERVIEW
    • FIGURE 35 MICROBA LIFE SCIENCES: COMPANY SNAPSHOT (2023)
    • 13.1.4 ILLUMINA INC.
    • TABLE 141 ILLUMINA INC.: COMPANY OVERVIEW
    • FIGURE 36 ILLUMINA INC.: COMPANY SNAPSHOT (2022)
    • 13.1.5 OXFORD NANOPORE TECHNOLOGIES, PLC
    • TABLE 142 OXFORD NANOPORE TECHNOLOGIES, PLC: COMPANY OVERVIEW
    • FIGURE 37 OXFORD NANOPORE TECHNOLOGIES, PLC.: COMPANY SNAPSHOT (2022)
    • 13.1.6 BIOME OXFORD LTD.
    • TABLE 143 BIOME OXFORD LTD.: COMPANY OVERVIEW
    • 13.1.7 VIENNALAB DIAGNOSTICS GMBH
    • TABLE 144 VIENNALAB DIAGNOSTICS GMBH: COMPANY OVERVIEW
    • 13.1.8 METABIOMICS (A SUBSIDIARY OF PRESCIENT MEDICINE HOLDINGS, INC.)
    • TABLE 145 METABIOMICS: COMPANY OVERVIEW
    • 13.1.9 VIOME LIFE SCIENCES
    • TABLE 146 VIOME LIFE SCIENCES: COMPANY OVERVIEW
    • 13.1.10 LUXIA SCIENTIFIC
    • TABLE 147 LUXIA SCIENTIFIC: COMPANY OVERVIEW
    • 13.1.11 SUN GENOMICS
    • TABLE 148 SUN GENOMICS: COMPANY OVERVIEW
    • 13.1.12 ATLAS BIOMED
    • TABLE 149 ATLAS BIOMED: COMPANY OVERVIEW
    • 13.1.13 QUANTBIOME, INC. (DBA OMBRE)
    • TABLE 150 QUANTBIOME, INC.: COMPANY OVERVIEW
    • 13.1.14 BECTON, DICKINSON AND COMPANY
    • TABLE 151 BECTON, DICKINSON AND COMPANY: COMPANY OVERVIEW
    • FIGURE 38 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2022)
    • 13.1.15 DAYTWO
    • TABLE 152 DAYTWO: COMPANY OVERVIEW
  • *Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments might not be captured in case of unlisted companies.
  • 13.2 OTHER PLAYERS
    • 13.2.1 MICRONOMA
    • 13.2.2 TERAOMICS S.L.
    • 13.2.3 FLIGHTPATH BIOSCIENCES
    • 13.2.4 MICROBIOME RESEARCH PVT. LTD.
    • 13.2.5 ORIGIN SCIENCES
    • 13.2.6 LEUCINE RICH BIO PRIVATE LIMITED
    • 13.2.7 DECODE AGE
    • 13.2.8 EVVY
    • 13.2.9 ALPHABIOMICS, LTD.
    • 13.2.10 GOODGUT

14 APPENDIX

  • 14.1 DISCUSSION GUIDE
  • 14.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 14.3 CUSTOMIZATION OPTIONS
  • 14.4 RELATED REPORTS
  • 14.5 AUTHOR DETAILS
비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제